Skip to main content

-

Technology Guidance - Drug

Adalimumab for treating active moderate to severe hidradenitis suppurativa Published on 2 May 2019


Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Adalimumab 40 mg/0.8 ml solution for injection (prefilled syringe and pen) for treating active moderate to severe hidradenitis suppurativa (acne inversa), defined by Hurley stage II or III disease in patients with an inadequate response to conventional systemic therapy.
Prescribing clinicians should assess the patient's initial response to adalimumab after 12 weeks of treatment, and only continue if there is clear evidence of Hidradenitis Suppurativa Clinical Response (HiSCR), defined as:
  • A reduction of 50% or more from baseline in total abscess and inflammatory nodule count; and
  • No increase in abscess or draining-fistula count.

Subsidy status

Adalimumab 40 mg/0.8 ml solution for injection (prefilled syringe and pen) is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

Adalimumab should be used in line with the clinical criteria in the MAF checklist for initial and continuing prescriptions for patients with hidradenitis suppurativa.

MAF assistance does not apply to adalimumab 40 mg/0.4 ml solution for injection.


Get Acrobat Readeropens in a new window
Back to Top